World's Best Scientists 2026 revealed!
Thomas E. Hutson

Thomas E. Hutson

D-Index & Metrics

Medicine

D-Index
81
Citations
60511
World Ranking
16357
National Ranking
8227

Overview

Thomas E. Hutson is affiliated with Texas Oncology in the United States. Their research focuses primarily on the treatment of renal cell carcinoma and related cancers, with significant work in cancer immunotherapy, biomarkers, oncology, and molecular biology.

They have contributed to various fields of study, including:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader disciplines, their subfields of study include:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Economics and Econometrics
  • Molecular Biology

Thomas E. Hutson's main research topics cover:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Renal and related cancers
  • Economic and Financial Impacts of Cancer
  • Bladder and Urothelial Cancer Treatments
  • Pancreatic and Hepatic Oncology Research

The scientist frequently publishes in several academic journals, with the most common venues being:

  • Journal of Clinical Oncology
  • The Oncologist
  • Annals of Oncology
  • Clinical Genitourinary Cancer
  • European Urology

Frequent co-authors working alongside Thomas E. Hutson include:

  • Camillo Porta
  • Robert J. Motzer
  • Toni K. Choueiri
  • Viktor Grünwald
  • Sumanta K. Pal

Representative recent publications authored or co-authored by Thomas E. Hutson include:

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, 2021, New England Journal of Medicine
  • Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, 2022, The Lancet Oncology
  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, 2023, Journal of Clinical Oncology
  • Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study, 2023, The Lancet Oncology
  • Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial, 2022, Journal for ImmunoTherapy of Cancer

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

    Fei Su;Amaya Viros;Carla Milagre;Kerstin Trunzer

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

    Robert J Motzer;Thomas E Hutson;Hilary Glen;M Dror Michaelson

  • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    Robert J Motzer;Bernard Escudier;Piotr Tomczak;Thomas E Hutson

  • Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    Matthew D. Galsky;Noah M. Hahn;Jonathan Rosenberg;Guru Sonpavde

  • Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

    Bernard Escudier;Cezary Szczylik;Thomas E. Hutson;Tomasz Demkow

  • Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

    Robert J. Motzer;Dmitry Nosov;Timothy Eisen;Igor Bondarenko

Frequent Co-Authors

Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Toni K. Choueiri
Toni K. Choueiri Harvard University
Cora N. Sternberg
Cora N. Sternberg Cornell University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Thomas Powles
Thomas Powles Queen Mary University of London
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Robert A. Figlin
Robert A. Figlin Cedars-Sinai Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary education options can be a smart move for students interested in healthcare careers beyond a traditional MD. Many professionals choose to pursue further education in areas like hospital management, advanced nursing, pharmacy, or health information systems.

If you're interested in leadership roles in healthcare settings, consider the cheapest master's in healthcare administration programs available online. This pathway helps prepare you for managerial positions across the healthcare industry.

Nurses aiming for advanced clinical or executive positions may benefit from enrolling in one of the least expensive dnp programs. These flexible, online Doctor of Nursing Practice programs can open doors to higher-paying roles and increased responsibility.

For those interested in medication management or research, an accredited pharmacy degree online offers another respected career pathway.

Alternatively, technology-driven students can help transform patient care by pursuing an online bachelor's in health information management, equipping graduates with the skills to organize and secure medical data in healthcare settings.

Best Scientists Citing Thomas E. Hutson

Trending Scientists

Recently Published Articles